70518-3512 Ondansetron

Product NDC:

70518-3512

Brand Name:

Ondansetron

Generic Name:

Ondansetron

Dosage Form Name:

TABLET, ORALLY DISINTEGRATING

Administration Route:

Oral

Substances:

Name: ONDANSETRON

Strength: 4.0

Unit: mg/1

Packages:

Code: 70518-3512-00

Description: 30 TABLET, ORALLY DISINTEGRATING in 1 BOX, UNIT-DOSE (70518-3512-0)

Effective Date: Sept. 7, 2022

Discontinued:

Code: 70518-3512-01

Description: 6 TABLET, ORALLY DISINTEGRATING in 1 BOX, UNIT-DOSE (70518-3512-1)

Effective Date: Sept. 29, 2022

Discontinued:

Code: 70518-3512-02

Description: 10 TABLET, ORALLY DISINTEGRATING in 1 BOX, UNIT-DOSE (70518-3512-2)

Effective Date: Oct. 20, 2023

Discontinued:

Code: 70518-3512-03

Description: 20 TABLET, ORALLY DISINTEGRATING in 1 BOX, UNIT-DOSE (70518-3512-3)

Effective Date: Oct. 31, 2023

Discontinued:

Code: 70518-3512-04

Description: 12 TABLET, ORALLY DISINTEGRATING in 1 BOX, UNIT-DOSE (70518-3512-4)

Effective Date: Nov. 20, 2023

Discontinued:

Code: 70518-3512-05

Description: 9 TABLET, ORALLY DISINTEGRATING in 1 BOX, UNIT-DOSE (70518-3512-5)

Effective Date: Dec. 23, 2023

Discontinued:

Code: 70518-3512-06

Description: 21 TABLET, ORALLY DISINTEGRATING in 1 BOX, UNIT-DOSE (70518-3512-6)

Effective Date: Jan. 14, 2024

Discontinued:

SEER*Rx Category:

Ancillary Therapy

Major Class:

Antiemetic

Minor Class:

5HT3 Receptor Antagonist

Orphan Drug Designation:

Status:

In Use

CanMED and the Oncology Toolbox

CanMED: NDC